Derazantinib; ARQ-087
Cikakken Bayani
Tags samfurin
| Girman Kunshin | samuwa | Farashin (USD) |
| 10mg | A Stock | 800 |
| 100mg | A Stock | 1200 |
| 500mg | A Stock | 1800 |
| Ƙarin Girman Girma | Samu Magana | Samu Magana |
Sunan Sinadari:
(6R) -6- (2-fluorophenyl) -5,6-dihydro-N-[3-[2-[(2-methoxyethyl) amino] ethyl] phenyl] -Benzo[h] quinazolin-2-amine
Lambar SMILES:
COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1
Lambar InChi:
InChi=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24- 10-4-5-12-2 7(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H ,32,33,34)/t26-/m1/s1
InChi Key:
KPJDVVCDVBFRMU-AREMUKBSSA-N
Mabuɗin kalma:
Derazantinib, ARQ-087, ARQ087, ARQ 087, 1234356-69-4
Solubility:Mai narkewa a cikin DMSO
Ajiya:0 - 4°C na gajeren lokaci (kwanaki zuwa makonni), ko -20°C na dogon lokaci (watanni).
Bayani:
Derazantinib, wanda kuma aka sani da ARQ-087, shine mai hanawa ta baki na mai karɓar haɓakar haɓakar fibroblast (FGFR) tare da yuwuwar aikin antineoplastic. FGFR inhibitor ARQ 087 yana ɗaure zuwa kuma da ƙarfi yana hana ayyukan FGFR subtypes 1, 2 da 3. Wannan na iya haifar da hanawar hanyoyin watsa sigina na FGFR, haɓakar ƙwayar ƙwayar cuta, ƙwayar cutar angiogenesis da ƙwayar ƙwayar cuta a cikin FGFR-overexpressing ƙwayoyin ƙari. . FGFR, da karasalan Tyrosine, an ruwaito shi a cikin nau'ikan tumatir da yawa kuma yana taka muhimmiyar rawa a cikin tumo, bambance bambance, angioggenesis da rayuwa.
Saukewa: FGFR
